Robert Kreitman, MD
Enriched profileSenior Investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology · National Cancer Institute
Robert Kreitman is Senior Investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at National Cancer Institute. OpenAlex indexes 343 publications with 17,323 citations (h-index 71); ClinicalTrials.gov lists 26 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 21 Oct 2026
Robert Kreitman, MP, is Senior Investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at National Cancer Institute, National Institutes of Health. The public record shows 343 publications with 17,323 citations (h-index 71), centered on Toxin Mechanisms and Immunotoxins, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment. It also documents an investigator role on 26 registered clinical trials.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Toxin Mechanisms and Immunotoxins
- 26 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 206.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 26 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Sponsor: National Cancer Institute (NCI)
- Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Sponsor: National Cancer Institute (NCI)
- Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Sponsor: National Cancer Institute (NCI)
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 21 Oct 2026
41 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.
ASH Annual Meeting
ASH2025Co-author - Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts
ASH Annual Meeting
ASH2025Presenting author - Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia
ASH Annual Meeting
ASH2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.
Science translational medicine
Article2026 - Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy.
JCO precision oncology
Article2025 - Development of a distributed international patient data registry for hairy cell leukemia.
Leukemia & lymphoma
Article2022
Most-cited works
by citation count (OpenAlex)- 01
- 02Immunotoxin therapy of cancerReview529 citations2006
- 03
- 04
- 05
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
hairycellleukemia.org/blog/grantee-spotlight-kreitman
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hairycellleukemia.org ↗ - Other
irp.nih.gov/pi/robert-kreitman
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Ohio State University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hairycellleukemia.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hairycellleukemia.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Brown, MD
National Cancer Institute
Gregory Reaman, MD
National Cancer Institute
James Gulley, MD
National Cancer Institute
Kevin Conlon, MD
National Cancer Institute
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center